KaydedilenlerDerginizi ekleyin

Dergiler / Erciyes Medical Journal / 2021 / Cilt: 43 - Sayı: 3

An Overview of Clinical Studies on Endocan andCardiovascular Disease

Okan TANRIVERDİ
Lütfü AŞKIN
Sayfa
233–236
Yayın Tarihi
2022-10-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

We aimed to present a review of the biological functions of the endocan and the prevention of atherosclerosis.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Endothelial dysfunction is a catastrophic condition caused by disruption of the equilibrium between vasodilatation and vaso constriction.
📊
Temel Bulgular & Veri:Increased endocan levels cause atherosclerosis in hypertension and coronaryartery disease.
💡
Sonuç & Katkı:We aimed to present a review of the biological functions of the endocan and the prevention of atherosclerosis.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Endothelial dysfunction is a catastrophic condition caused by disruption of the equilibrium between vasodilatation and vaso constriction. Endocan is a proteoglycan derived from vascular endothelium. Endocan can interact with biologically active mol ecules, and these active molecules are essential for the balance of many biological functions, including cell adhesion, migration,proliferation, and new blood vessel formation. Increased endocan levels cause atherosclerosis in hypertension and coronaryartery disease. We aimed to present a review of the biological functions of the endocan and the prevention of atherosclerosis.

🔖

Bu Makaleye Atıf Yap

TANRIVERDİ, O., AŞKIN, L. (2022). An Overview of Clinical Studies on Endocan andCardiovascular Disease. Erciyes Medical Journal, Cilt: 43 - Sayı: 3, 233–236. https://ajindex.com/articles/502331

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Balta S, Ozturk C. The relation between CD40 ligand and coronary artery disease. Cardiology 2015; 131(2): 107–8
  2. Balta I, Balta S, Demirkol S, Celik T, Ekiz O, Cakar M, et al. Aortic arterial stiffness is a moderate predictor of cardiovascular disease in patients with psoriasis vulgaris. Angiology 2014; 65(1): 74–8
  3. Karaman M, Balta S, Ahmet AY, Cakar M, Naharci I, Demirkol S, et al. The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension. Clin Exp Hypertens 2013; 35(7): 516–22
  4. Altun B, Bulucu F, Demirbas S, Karaman M, Ay SA, Cakar M, et al. The relationship between some of the cardiovascular risk factors and arterial stiffness parameters in essentially hypertensive patients. Clin Exp Hypertens 2013; 35(6): 444–8
  5. Balta S, Demirkol S, Celik T, Kucuk U, Unlu M, Arslan Z, et al. Association between coronary artery ectasia and neutrophil-lymphocyte ratio. Angiology 2013; 64(8): 627–32
  6. Stéphane S, Claude-Alain M, Dominique D, Philippe L, Maryse D. Endocan as a biomarker of endothelial dysfunction in cancer. J Cancer Sci Ther 2010; 2(2): 47–52
  7. Kali A, Shetty KS. Endocan: A novel circulating proteoglycan. Indian J Pharmacol 2014; 46(6): 579–83
  8. Balta I, Balta S, Koryurek OM, Demirkol S, Mikhailidis DP, Celik T, et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol 2014; 70(2): 291–6
  9. Balta I, Balta S, Demirkol S, Mikhailidis DP, Celik T, Akhan M, et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: Correlations with cardiovascular risk and activity of disease. Br J Dermatol 2013; 169(5): 1066–70
  10. Balta S, Mikhailidis DP, Demirkol S, Celik T, Ozturk C, Iyisoy A. Endocan and atherosclerosis. Angiology 2015; 66(5): 490
  11. Lee W, Ku SK, Kim SW, Bae JS. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol 2014; 229(5): 620–30
  12. Béchard D, Scherpereel A, Hammad H, Gentina T, Tsicopoulos A, Aumercier M, et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 2001; 167(6): 3099–106
  13. Kose M, Emet S, Akpinar TS, Kocaaga M, Cakmak R, Akarsu M, et al. Serum endocan level and the severity of coronary artery disease: A pilot study. Angiology 2015; 66(8): 727–31
  14. Unlu M, Karaman M, Ay SA, Balta S, Cakar M, Demirkol S, et al. The